medigraphic.com
Colegio de Medicina Interna de México.

2023, Número 6

<< Anterior Siguiente >>

Med Int Mex 2023; 39 (6)


Nefroprotección inmediata en nefropatía inducida por medios de contraste

González AFE, Russi LJA, Sáenz MOA, Celemín FCA, Baquero LGA, Bocanegra DDM

Idioma: Español
Referencias bibliográficas: 35
Paginas: 899-907
Archivo PDF: 216.92 Kb.


RESUMEN

La nefropatía inducida por medios de contraste y la nefroprotección son temas de gran importancia para muchas de las diferentes áreas médicas por motivos diagnósticos en estudios radiológicos con uso de contrastes yodados y por motivos terapéuticos en la intervención coronaria percutánea, donde tiene clara relación el tipo de medio de contraste, su cantidad y otros factores del paciente con la posible aparición de nefropatía inducida por estos agentes. Este artículo revisa el riesgo de nefropatía por medios de contraste sobre todo yodados, así como de las diferentes medidas terapéuticas nefroprotectoras disponibles.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Aspelin P, Aubry P, Fransson S-G, Strasser R, WillenbrockR, Berg KJ. Nephrotoxic effects in high-risk patients undergoingangiography. N Engl J Med 2003; 348 (6): 491-9. doi:10.1056/NEJMoa021833.

  2. Ribichini F, Graziani M, Gambaro G, Pasoli P, et al. Earlycreatinine shifts predict contrast-induced nephropathyand persistent renal damage after anigiography. Am J Med2010; 123: 755-63. doi: 10.1016/j.amjmed.2010.02.026.

  3. Kidney Disease Improving Global Outcomes (KDIGO).Clinical practice guideline for acute kidney injury. KidneyInt Suppl 2012; 2: 1-138.

  4. Mehran R, Dangas GD, Weisbord SD. Contrast-associatedacute kidney injury. N Engl J Med 2019; 380: 2146-55. DOI:10.1056/NEJ Mra1805256.

  5. Recio-Mayoral A, Chaparro M, Prado B, Cózar R, et al. Thereno-protective effect of hydration with sodium bicarbonateplus n-acetylcysteine in patients undergoing emergencypercutaneous coronary intervention: the RENO study.J Am Coll Cardiol 2007; 49 (12): 1283-8. doi: 10.1016/j.jacc.2006.11.034.

  6. Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies forcontrast-induced nephropathy. JAMA 2006; 295 (23):2765-79. doi:10.1001/jama.295.23.2765.

  7. Laskey W, Jenkins C, Selzer F, Marroquin OC, et al. Volumeto-creatinine clearance ratio: A pharmacokinetically basedrisk factor for prediction of early creatinine increase afterpercutaneous coronary intervention. J Am Coll Cardiol2007; 50: 584-90. doi: 10.1016/j.jacc.2007.03.058.

  8. Mehran R, Aymong ED, Nikolsky E, Lasic Z, et al. A simplerisk score for prediction of contrast-induced nephropathyafter percutaneous coronary intervention: developmentand initial validation. J Am Coll Cardiol 2004; 44 (7): 1393-9.doi: 10.1016/j.jacc.2004.06.068.

  9. Silver S, Shah P, Chertow G, Harel S, Wald R, Harel Z. Riskprediction models for contrast induced nephropathy:systematic review. BMJ 2015; 351: 4395. doi: 10.1136/bmj.h4395.

  10. Maioli M, Toso A, Gallopin M, Leoncini M, et al. Preproceduralscore for risk of contrast-induced nephropathyin elective coronary angiography and intervention.J Cardiovasc Med 2010; 11: 444-9. doi: 10.2459/JCM.0b013e328335227c.

  11. Nikolsky E, Mehran R, Lasic Z, et al. El hematocrito bajopredice nefropatía inducida por contraste después deintervenciones coronarias percutáneas. Riñón Int 2005;67: 706-713.

  12. Brar SS, Aharonian V, Mansukhani P, Moore N, Shen AY,Jorgensen M, et al. Haemodynamic-guided fluid administrationfor the prevention of contrast-induced acutekidney injury: the POSEIDON randomised controlled trial.Lancet 2014; 383 (9931): 1814-23. doi: 10.1016/S0140-6736(14)60689-9.

  13. Marenzi G, Ferrari C, Marana I, Assanelli E, Fabbiocchi F,Montorsi P, et al. Prevention of contrast nephropathy byfurosemide with matched hydration. JACC CardiovascularInterventions 2012; 5 (1): 90-7. https://doi.org/10.1016/j.jcin.2011.08.017.

  14. Murakami R, Kumita S, Hayashi H, Sugizaki K, et al. Anemiaand the risk of contrast-induced nephropathy in patientswith renal insufficiency undergoing contrast-enhancedMDCT. Eur J Radiol 2013; 82: e521-e524. http://dx.doi.org/10.1016/j.ejrad.2013.06.004.

  15. Hernández F, Mora L, García T, Velázquez M, Gómez-Blázquez I, et al. Comparación de iodixanol frente a ioversolen la prevención de la nefropatía por contraste trascoronariografía o angioplastia en pacientes diabéticos.Rev Esp Cardiol 2009; 62 (12): 1373-80. DOI: 10.1016/S0300-8932(09)73122-7.

  16. Klima T, Christ A, Marana I, Kalbermatter S, Uthoff H, BurriE, et al. Sodium chloride vs. sodium bicarbonate for theprevention of contrast medium-induced nephropathy: arandomized controlled trial. Eur Heart J 2012; 33 (16):2071-9. doi: 10.1093/eurheartj/ehr501.

  17. Reed M, Meier P, Tamhane UU, Welch KB, Moscucci M,Gurm HS. The relative renal safety of iodixanol comparedwith low-osmolar contrast media: a meta-analysis of randomizedcontrolled trials. JACC Cardiovasc Interv 2009; 2(7): 645-54. doi: 10.1016/j.jcin.2009.05.002.

  18. Fahling M, Seeliger E, Patzak A, Persson PB. Understandingand preventing contrast-induced acute kidney injury.Nat Rev Nephrol 2017; 13 (3): 169-180. doi: 10.1038/nrneph.2016.196.

  19. Kshirsagar AV, Poole C, Mottl A, Shoham D, et al. N-acetylcysteinefor the prevention of radiocontrast induced nephropathy:A meta-analysis of prospective controlled trials.J Am Soc Nephrol 2004; 15 (3): 761-9. doi: 10.1097/01.asn.0000116241.47678.49.

  20. Marenzi G, Assanelli E, Marana I, Lauri G, et al. N-acetylcysteineand contrast-induced nephropathy in primary angioplasty.N Engl J Med 2006; 354: 2773-82. doi: 10.1056/NEJMoa054209.

  21. Chong E, Poh k, Lu Q, Zhang J, et al. Comparison of combinationtherapy of high-dose oral N-acetylcysteine andintravenous sodium bicarbonate hydration with individualtherapies in the reduction of Contrast-induced Nephropathyduring Cardiac Catheterisation and PercutaneousCoronary Intervention (CONTRAST): A multi-centre, randomised,controlled trial. Int J Cardiol 2015; 201: 237-242.doi: 10.1016/j.ijcard.2015.07.108.

  22. Weisbord SD, Gallagher M, Jneid H, Garcia S, et al. Outcomesafter angiography with sodium bicarbonate andacetylcysteine. N Engl J Med 2018; 378 (7): 603-614. DOI:10.1056/NEJMoa1710933.

  23. Joannidis M, Schmid M, Wiedermann CJ. Prevention ofcontrast media-induced nephropathy by isotonic sodiumbicarbonate: a meta-analysis. Wien Klin Wochenschr 2008;120 (23-24): 742-8.

  24. Peruzzi M, De Luca L, Thomsen H, Romagnoli E, et al.A network meta analysis on randomized trials focusinon the preventive effect of statins on contrast inducednephropathy. Biomed Res Int 2014; 2014: 213239. doi:10.1155/2014/213239.

  25. Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D,et al. Statin therapy reduces contrast-induced nephropathy:an analysis of contemporary percutaneous interventions.Am J Med 2005; 118: 843-849. doi: 10.1016/j.amjmed.2005.03.031.

  26. Kaya A, Kurt M, Tanboga I, Isik T, et al. Rosuvastatin versusAtorvastatin to prevent Contrast /induced Nephropathyin patients undergoing primary percutaneous coronaryintervention (ROSA-cIN trial). Acta Cardioi 2013; 68 (5):488-494. doi: 10.1080/ac.68.5.2994472.

  27. Liu Y, Liu Y-h, Tan N, Chen J-y, Zhou Y-l, et al. Comparisonof the efficacy of rosuvastatin versus atorvastatin inpreventing contrast induced nephropathy in patient withchronic kidney disease undergoing percutaneous coronaryintervention. PLoS ONE 2014; 9 (10): e111124. https://doi.org/10.1371/journal.pone.0111124.

  28. Hoshi T, Sato A, Kakefuda Y, Harunari T, Hiroaki W, et al. Preventiveeffect of statin pretreatment on contrast-induced acutekidney injury in patients undergoing coronary angioplasty:Propensity score analysis from a multicenter registry. Int JCardiol 2014; 171: 243-249. doi: 10.1016/j.ijcard.2013.12.017.

  29. Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, et al.Short-term, high-dose atorvastatin pretreatment to preventcontrast-induced nephropathy in patients with acutecoronary syndromes undergoing percutaneous coronaryintervention (from the ARMYDA-CIN [atorvastatin for reductionof myocardial damage during angioplasty-contrastinducednephropathy] Trial. Am J Cardiol 2011; 108 (1): 1-7.doi: 10.1016/j.amjcard.2011.03.001.

  30. Shehata M, Hamza M. Impact of high loading dose ofatorvastatin in diabetic patients with renal dysfunctionundergoing elective percutaneous coronary intervention:a randomized controlled trial. Cardiovascular Ther 2015;33: 35-41. doi: 10.1111/1755-5922.12108.

  31. Gandhi S, Mosleh W, Abdel Qadir H, Farkouh M. Statinsand contrast-induced acute kidney injury with coronaryangiography. Am J Med 2014; 127 (10). 987-1000. doi:10.1016/j.amjmed.2014.05.011.

  32. Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, CampodonicoJ, Trabattoni D, Fabbiocchi F, Montorsi P, BartorelliA. The prevention of radiocontrast-agent-induced nephropathyby hemofiltration. N Engl J Med 2003; 349: 1333-40.doi: 10.1056/NEJMoa023204.

  33. Cruz DN, Goh CY, Marenzi G, Corradi V, Ronco C, PerazellaMA. Renal replacement therapies for prevention ofradiocontrast-induced nephropathy: a systematic review.Am J Med 2012; 125 (1): 66-78.e3. doi: 10.1016/j.amjmed.2011.06.029.

  34. Ozkok S, Ozkok A. Contrast-induced acute kidney injury:A review of practical points. World J Nephrol 2017; 6 (3):86-99. doi: 10.5527/wjn.v6.i3.86.

  35. Mehdi A, Taliercio JJ, Nakhoul G. Contrast media in patientswith kidney disease: An update. Cleve Clin J Med 2020; 87(11): 683-694. doi: 10.3949/ccjm.87a.20015.




2020     |     www.medigraphic.com